CN101568833B - 使用MR-proADM的糖尿病诊断和风险分级 - Google Patents
使用MR-proADM的糖尿病诊断和风险分级 Download PDFInfo
- Publication number
- CN101568833B CN101568833B CN200780041709.4A CN200780041709A CN101568833B CN 101568833 B CN101568833 B CN 101568833B CN 200780041709 A CN200780041709 A CN 200780041709A CN 101568833 B CN101568833 B CN 101568833B
- Authority
- CN
- China
- Prior art keywords
- diabetes
- use according
- proadm
- marker
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410442798.5A CN104198735B (zh) | 2006-11-08 | 2007-11-08 | 使用MR‑proADM的糖尿病诊断和风险分级 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006052916A DE102006052916A1 (de) | 2006-11-08 | 2006-11-08 | Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM |
| DE102006052916.2 | 2006-11-08 | ||
| PCT/DE2007/002018 WO2008055491A2 (de) | 2006-11-08 | 2007-11-08 | Diagnose und risikostratifizierung von diabetes mellitus mittels mr-proadm |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410442798.5A Division CN104198735B (zh) | 2006-11-08 | 2007-11-08 | 使用MR‑proADM的糖尿病诊断和风险分级 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101568833A CN101568833A (zh) | 2009-10-28 |
| CN101568833B true CN101568833B (zh) | 2014-09-10 |
Family
ID=39277540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200780041709.4A Active CN101568833B (zh) | 2006-11-08 | 2007-11-08 | 使用MR-proADM的糖尿病诊断和风险分级 |
| CN201410442798.5A Active CN104198735B (zh) | 2006-11-08 | 2007-11-08 | 使用MR‑proADM的糖尿病诊断和风险分级 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410442798.5A Active CN104198735B (zh) | 2006-11-08 | 2007-11-08 | 使用MR‑proADM的糖尿病诊断和风险分级 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20100035275A1 (enExample) |
| EP (1) | EP2097748B1 (enExample) |
| JP (2) | JP5275247B2 (enExample) |
| CN (2) | CN101568833B (enExample) |
| DE (1) | DE102006052916A1 (enExample) |
| ES (1) | ES2393262T3 (enExample) |
| WO (1) | WO2008055491A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8906857B2 (en) * | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
| US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| EP2016394A4 (en) | 2006-04-04 | 2013-04-24 | Singulex Inc | METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES |
| DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| ES2795003T3 (es) * | 2008-10-07 | 2020-11-20 | Brahms Gmbh | Biomarcador para la predicción de los primeros eventos adversos |
| EP2180322A1 (en) * | 2008-10-22 | 2010-04-28 | BRAHMS Aktiengesellschaft | Prognostic biomarkers for the progression of primary chronic kidney disease |
| US20110262939A1 (en) * | 2008-10-31 | 2011-10-27 | B.R.A.H.M.S Gmbh | Methods and assays for classifying foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system |
| CN102203608B (zh) * | 2008-10-31 | 2016-11-23 | B.R.A.H.M.S有限公司 | 用于与代谢综合征、心血管疾病和/或胰岛素抗性相关的病症的诊断、预后、监测和治疗追踪的体外方法 |
| JP5584695B2 (ja) * | 2008-11-11 | 2014-09-03 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Adm及びbnpのレベルを決定することによる心疾患に罹患した患者の予後診断及びリスク評価 |
| AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
| CN102472752B (zh) * | 2009-08-28 | 2015-08-19 | B.R.A.H.M.S有限公司 | 用于不良事件的预后的降钙素原 |
| RU2017110678A (ru) * | 2010-11-01 | 2019-01-24 | Б.Р.А.Х.М.С Гмбх | Оценка прогноза и риска пациентов с неспецифическими жалобами |
| AU2012219582A1 (en) * | 2011-02-21 | 2013-08-22 | Fibrostatin S.L. | Methods for treating and diagnosing disease |
| EP2533052A1 (en) * | 2011-06-07 | 2012-12-12 | B.R.A.H.M.S GmbH | Diagnostic use of proSomatostatin |
| CN104714020B (zh) * | 2013-12-12 | 2016-05-25 | 张曼 | 尿液内源性α胰蛋白酶抑制剂重链H4在2型糖尿病合并冠心病中的应用 |
| CN119199150A (zh) * | 2015-11-27 | 2024-12-27 | B.R.A.H.M.S 有限公司 | 作为对象的细胞外容量状态的标志物的MR-proADM |
| RU2765212C2 (ru) * | 2016-08-09 | 2022-01-26 | Б.Р.А.Х.М.С. Гмбх | Гистоны и/или proadm в качестве маркеров, свидетельствующих о неблагоприятном событии |
| JP7194673B2 (ja) * | 2016-08-09 | 2022-12-22 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 臓器障害を示すマーカーとしてのヒストンおよび/またはproADM |
| EP3438668A1 (en) * | 2017-08-04 | 2019-02-06 | B.R.A.H.M.S GmbH | Diagnosis and risk stratification of fungal infections |
| EP3682247B1 (en) * | 2017-09-13 | 2022-02-09 | B.R.A.H.M.S GmbH | Proadrenomedullin as a marker for abnormal platelet levels |
| US11892456B2 (en) * | 2017-11-17 | 2024-02-06 | Tokai University Educational System | Method of examining diabetic complication |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997007214A1 (en) * | 1995-08-18 | 1997-02-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19847690A1 (de) * | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| US6756783B2 (en) * | 1999-06-01 | 2004-06-29 | Merlin Technology, Inc | Multi-frequency boring tool locating system and method |
| ES2254220T3 (es) * | 1999-09-10 | 2006-06-16 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Determinacion de proteinas de enlace con la adrnomedulina. |
| DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| WO2004097423A1 (en) * | 2003-04-25 | 2004-11-11 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
| ES2300681T3 (es) * | 2004-07-22 | 2008-06-16 | Brahms Aktiengesellschaft | Procedimiento para el diagnostico y tratamiento de pacientes criticos con endotelina, agonistas de endotelina y antagonistas de adrenomedulina. |
| GB2418995B (en) * | 2004-09-29 | 2006-08-16 | Bookham Technology Plc | Apodised binary grating |
| FI20050011L (fi) * | 2005-01-05 | 2006-07-06 | Jurilab Ltd Oy | Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi |
-
2006
- 2006-11-08 DE DE102006052916A patent/DE102006052916A1/de not_active Withdrawn
-
2007
- 2007-11-08 EP EP07866202A patent/EP2097748B1/de active Active
- 2007-11-08 CN CN200780041709.4A patent/CN101568833B/zh active Active
- 2007-11-08 US US12/514,194 patent/US20100035275A1/en not_active Abandoned
- 2007-11-08 ES ES07866202T patent/ES2393262T3/es active Active
- 2007-11-08 JP JP2009535557A patent/JP5275247B2/ja active Active
- 2007-11-08 CN CN201410442798.5A patent/CN104198735B/zh active Active
- 2007-11-08 WO PCT/DE2007/002018 patent/WO2008055491A2/de not_active Ceased
-
2012
- 2012-10-25 JP JP2012235494A patent/JP2013047689A/ja active Pending
-
2016
- 2016-02-26 US US15/055,406 patent/US20160169912A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997007214A1 (en) * | 1995-08-18 | 1997-02-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology |
Non-Patent Citations (2)
| Title |
|---|
| Jerzy Beltowski ET AL..ADRENOMEDULLIN – WHAT DO WE KNOW 10 YEARS SINCE ITS DISCOVERY?.《POLISH JOURNAL OF PHARMACOLOGY》.2004,第56卷第5-27页. * |
| NILS G. MORGENTHALER ET AL..Measurement of Midregional Proadrenomedullin in Plasma with an Immunoluminometric Assay.《CLINICAL CHEMISTRY》.2005,第51卷(第10期),第1824页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5275247B2 (ja) | 2013-08-28 |
| DE102006052916A1 (de) | 2008-05-15 |
| CN101568833A (zh) | 2009-10-28 |
| CN104198735B (zh) | 2018-01-30 |
| JP2010509575A (ja) | 2010-03-25 |
| US20100035275A1 (en) | 2010-02-11 |
| WO2008055491A2 (de) | 2008-05-15 |
| CN104198735A (zh) | 2014-12-10 |
| HK1203090A1 (en) | 2015-10-16 |
| WO2008055491A3 (de) | 2008-08-21 |
| HK1137805A1 (en) | 2010-08-06 |
| US20160169912A1 (en) | 2016-06-16 |
| JP2013047689A (ja) | 2013-03-07 |
| ES2393262T3 (es) | 2012-12-19 |
| EP2097748A2 (de) | 2009-09-09 |
| EP2097748B1 (de) | 2012-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101568833B (zh) | 使用MR-proADM的糖尿病诊断和风险分级 | |
| EP2095107B1 (en) | Methods for risk assignment | |
| CN102449486B (zh) | 在患有呼吸困难的对象中检测细菌感染 | |
| US20100086944A1 (en) | Methods and Compositions for Diagnosis and Prognosis of Renal Artery Stenosis | |
| EP2376919B1 (en) | Combined natriuretic peptide assays | |
| CN101646945A (zh) | 利用CT-proET-1与NT-proBNP的组合进行急性冠状动脉综合征的诊断和风险分层 | |
| CN107064525A (zh) | 用于测定患有心脏病或被怀疑发生或患有心脏病的患者中的氨基末端proANP的方法 | |
| EP2425255A1 (en) | Means and methods for diagnosing a heart failure associated kidney damage in individuals in need of a suitable therapy | |
| CN102203608B (zh) | 用于与代谢综合征、心血管疾病和/或胰岛素抗性相关的病症的诊断、预后、监测和治疗追踪的体外方法 | |
| US20110263438A1 (en) | Diagnosis and complication risk assessment of pancreatic diabetes using procalcitonin | |
| JP4734306B2 (ja) | ナトリウム利尿ペプチドおよび胎盤増殖因子/可溶性vegf受容体を用いた、妊婦での心疾患に関連した心機能不全と胎盤関連心機能不全とを区別するための方法 | |
| DK2596010T3 (en) | SIGNAL biomarkers | |
| US20110081725A1 (en) | Assessment of complications of patients with type 1 diabetes | |
| HK1137805B (en) | Diagnosis and risk assessment of pancreatic diabetes using mr-proadm | |
| HK1203090B (en) | Diagnosis and risk assessment of pancreatic diabetes using mr-proadm | |
| Alan et al. | Use of biomarkers in evaluation of patients with heart failure | |
| Indumathi et al. | A review on application of biomarkers in heart failure | |
| WO2025133235A1 (en) | Adm-gly as marker for early predicting sepsis | |
| Haase et al. | Novel Biomarkers of Acute Cardiorenal Disease | |
| WO2023208993A1 (en) | Biomarkers of diabetic nephropathy | |
| HK1167273B (en) | Detection of bacterial infections in subjects suffering from dyspnea | |
| WO2010018123A1 (en) | Retinol binding protein 4 as a marker of peripheral insulin resistance in type 1 diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1137805 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: German Hennings Dov Applicant after: BRAHMS AG Address before: German Hennings Dov Applicant before: Brahms AG |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: BRAHMS AG TO: BRAHMS CO., LTD. |
|
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1137805 Country of ref document: HK |